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Background Myelin oligodendrocyte glycoprotein
(MOG) antibodies have been recently described in
children with acute disseminating encephalomyelitis
(ADEM), but the clinical and neuroradiological
characterisation of this subgroup is lacking.
Objective To compare the clinical and neuroradiological
features of paediatric ADEM with and without MOG
antibodies.
Methods Clinical course, cerebrospinal fluid (CSF)-,
MRI studies, outcome and MOG status of 33 paediatric
ADEM prospectively studied were reviewed.
Results MOG antibodies (median 1:2560; range
1:160–1:20 480) were detected in 19 children with
ADEM. The majority of children showed a decline of
serum MOG-IgG titres over time. Children with MOG
antibodies did not differ in their age at presentation, sex
ratio, the presence of oligoclonal bands, clinical
symptoms or initial severity, apart from a higher CSF cell
count (p=0.038), compared with children without MOG
antibodies. In addition, further relapsing demyelinating
episodes associated with MOG antibodies were observed
only in children with MOG antibodies. All 19 children
with MOG antibodies had a uniform MRI pattern,
characterised by large, hazy and bilateral lesions and the
absence of atypical MRI features (eg, mainly small
lesions, well-defined lesions), which was significantly
different compared to that of children without MOG
antibodies (p=0.003; and p=0.032, respectively). In
addition, children with MOG antibodies had involvement
of more anatomical areas (p=0.035) including the
myelon characterised by a longitudinally extensive
transverse myelitis (p=0.003), more often a complete
resolution of lesions (p=0.036) and a better outcome
(p=0.038).
Conclusions Patients with ADEM with MOG
antibodies in our cohort had a uniform MRI
characterised by large, bilateral and widespread lesions
with an increased frequency of longitudinal extensive
transverse myelitis and a favourable clinical outcome in
contrast to children lacking MOG antibodies.
INTRODUCTION
Acute disseminated encephalomyelitis (ADEM) syn-
drome is characterised by a clinical polyfocal event
of the central nervous system (CNS) with an
encephalopathy ranging from behavioural change
to alteration in consciousness.1 Brain MRI usually
shows diffuse, poorly demarcated and bilateral
lesions involving most predominantly the cerebral
white matter and spine.2 ADEM commonly follows
a monophasic disease course and is associated with
a good prognosis. However, a small subset of chil-
dren with ADEM can have more than one event.1
Relapsing disease following ADEM indicates a
chronic disorder and most often leads to the diag-
nosis of multiple sclerosis (MS) or neuromyelitis
optica (NMO).3–6
Biomarkers predicting the course of the disease
are lacking. Recently, it has been shown that serum
IgG antibodies to myelin oligodendrocyte glycopro-
tein (MOG) are present in approximately up to
40% children with ADEM.7–10 Typically, MOG
antibodies drop to undetectable levels in follow-up
samples of children with monophasic disease.7 8
Further, recent studies using cell-based immu-
noassays have demonstrated the presence of
MOG-IgG antibodies in paediatric patients with
MS, aquaporin-(AQP)-4-antibody seronegative
NMO, isolated optic neuritis (ON) or transverse
myelitis (TM), but only rarely in adult patients with
these disorders.11–16
We delineate the clinical and neuroradiological
features and outcome of children with ADEM
according to the serum MOG antibody status.
METHODS
Patients
Between 2009 and 2013, 231 children with a sus-
pected acute demyelinating event such as ADEM,
ON, NMO or a clinically isolated syndrome (CIS)
were sent to our attention from different hospitals
in Germany, Austria and Italy for further testing of
serum MOG-IgG and AQP4-IgG antibodies and
included in an ongoing prospective study.
From this cohort, 39 paediatric patients were ini-
tially identified who fulfilled the diagnostic criteria
of ADEM based on the International Paediatric MS
Study Group (IPMSSG) recommendations which
included a first polyfocal, clinical CNS event with a
presumed inflammatory demyelinating cause,
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encephalopathy that cannot be explained by fever, systemic
illness or postictal symptoms and an abnormal brain MRI
during the acute phase compatible with ADEM and not indica-
tive of another CNS disease.1 In addition, all children should
have had a complete set of investigations (clinical information,
cerebrospinal fluid (CSF) studies, MRI, serum sample). Six chil-
dren were subsequently excluded because they were assigned an
alternative diagnosis on follow-up (figure 1).
The majority of the final cohort of 33 children had a sero-
logical, immunological workup (white blood cells, antinuclear
antibodies), metabolic screen (eg, serum lactate, amino acids and
urinary organic acids) and CSF studies (cell count, oligoclonal
bands (OCBs)) at the referring hospital. All 33 children were
seen subsequently by the referring physicians. Clinical follow-up
information including neurological symptoms and the presence
of cognitive problems (eg, learning or attentional problems) and
other sequelae (eg, epilepsy) was obtained via a standardised
questionnaire in the majority of cases filled out by the referring
physicians in general every 6 months–1 year.
All MRI studies were assessed including the following
sequences (MB, TG, GK): T2-axial, fluid attenuated inversion
recovery-axial, T2-sagittal, T1-axial with a contrast medium,
myelon T2-sagittal and T1-sagittal with a contrast medium.
Each MRI was then scored according to the location of lesions
in five anatomical areas and assigned a score between 1 and 5
(supratentorial white matter ( juxtacortical, non-juxtacortical
and non-periventricular white matter, periventricular white
matter and corpus callosum); thalamus/basal ganglia; brainstem;
cerebellum; myelon with and without longitudinal extensive
TM (LETM)) (KR, MB).17 In 3/33 children, the scores obtained
by the two reviewers were different. MRIs of these children
were reviewed and consensus agreement was reached.
In a second step, the configuration of lesions (blurred/hazy,
large (>2 cm on the axial sequence) or contrast-enhancing) was
analysed and scored with yes or no (KR, MB). No differences
between the reviewers were recorded.
In addition, the following MRI features were classified as
atypical for ADEM: lesions only in one anatomical area, well-
defined lesions, diffuse white matter involvement without clear
lesional character, T1- hypointense lesions, predominantly small
lesions <2 cm, periventricular lesions, lesions perpendicular to
the corpus callosum or cortical lesions. In children who had a
combination of atypical features such as well-defined lesions
together with a periventricular or perpendicular location to the
long axis of the corpus callosum, we additionally classified this
pattern as an MS-like pattern.18 The presence of more than one
atypical feature classified the MRI as atypical for ADEM. In the
category atypical features, 17 features were described. In three
children, the reviewers differed in their judgement. The corre-
sponding MRIs were reviewed and consensus agreement was
reached.
MRI follow-up studies were available from 31/33 children and
compared in the same fashion as the initial MRIs. In order to
compare the initial with the follow-up MRI results, the findings
were categorised into four subgroups: complete resolution,
minor residuals (few remaining T2 signal changes, but much
improved), moderate residuals (only minor improvement of T2
signal changes) and marked residuals (eg, atrophy) (MB and KR).
In 29/39 children, MRI was performed on scanners with a
field strength of 1.5 T, in 7/39 children with a 3.0 T scanner and
in 3/39 children with a 1.0 T scanner.
All serum samples were analysed for the presence of
MOG-IgG and AQP4-IgG antibodies by cell-based assays as pre-
viously described and were obtained before anti-inflammatory
therapy with steroids was started.8 19 Screening was performed
at dilutions of 1:20 and 1:40 by at least two independent clinic-
ally blinded investigators (KS, SM and MR), and positive serum
samples were further diluted to determine the titre levels of
antibodies. Titre levels of ≥1:160 were classified as high titres as
previously described.8 Serum follow-up MOG samples were
tested from 25 children.
Statistical analysis
Statistical analysis was performed using IBM SPSS, release
V.18.0 (IBM Corporation). We compared clinical, demographic,
neuroradiological and serological data using the Kruskal-Wallis
test, Mann-Whitney test, Wilcoxon rank test, Fisher exact test
and χ2 test. Statistical significance was defined as a two-sided p
value of less than 0.05, and Bonferroni corrections were made
for multiple comparisons when appropriate.
RESULTS
Patients
From a cohort of 231 children with a first demyelinating event,
39 patients were diagnosed with ADEM, 74 with CIS/MS, 44
paediatric patients had ON, eight had TM and 21 had NMO.1
Eight children were diagnosed with an episode of acute cerebel-
litis, 27 had other inflammatory neurological diseases (eg, neu-
roborreliosis) and 10 children had other neurological diseases
(OND, eg, migraine; figure 1).
Initially, we included all 39 children diagnosed with ADEM
(figure 1). Six children were subsequently excluded because they
were assigned a different diagnosis on follow-up including MS
(n=1), Guillain-Barré syndrome (n=1), epilepsy due to a
KCNQ2 mutation (n=1), CNS vasculitis (n=2) and tick-borne
encephalitis (n=1).
The final cohort of 33 paediatric ADEM consisted of 15 girls
and 18 boys with a median age of 5 years (range 1–17 years)
Figure 1 Flow chart Study profile. AC, acute cerebellitis; ADEM, acute
disseminating encephalomyelitis, CIS, clinical isolated syndrome; MOG,
myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; OIND,
other inflammatory neurological diseases; ON, optic neuritis; OND,
other neurological diseases; NMO, neuromyelitis optica; TM, transverse
myelitis.
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and a median follow-up of 27 months (range 5–92 months). All
33 children were treated with intravenous methylprednisolone;
9 children received additional immunomodulatory treatments
(see online supplementary eTable 1).
Serum antibody status to MOG and AQP4
In a first step, the presence of serum IgG antibodies to MOG
and AQP4 were evaluated with a live cell staining immunofluor-
escence assay, as previously described.8 19 20 All 33 children
were tested negative for AQP4-IgG antibodies (data not shown).
In 19/33 (58%) patients with ADEM, serum MOG-IgG anti-
bodies of ≥1:160 (high titre) were detected (median 1:5120,
range 1:160–1:20 480; table 1). No child from the MOG nega-
tive group had detectable MOG antibodies in the lower range
(1:20–1:80). Seventeen out of 19 children had a titre of 1:1280
or higher, whereas only 2/19 children had MOG-IgG titres of
1:160. At the last follow-up, 8/18 children were still positive for
MOG-IgG antibodies and 16/18 children showed a decline of
>2 titre levels of serum MOG-IgG titres over time (median
MOG titre at last follow-up 1:80, range: 0–1:5120). There were
no significant differences in the follow-up time between patients
who were MOG-IgG positive (median 30, range 9–72 months)
or MOG-IgG negative (median 27, range 5–92 months) at last
follow-up.
To further analyse if children with (n=19) and without
(n=14) serum MOG-IgG antibodies revealed any differences,
we compared both subgroups (table 1).
Demographic and clinical data
Children with or without MOG antibodies did not differ in
their age, sex ratio and range of clinical symptoms, apart from a
higher number of CSF white blood cells and, less often, emo-
tional or behavioural problems at initial presentation (p=0.038
and p=0.026, respectively) (table 1).
Interestingly, 4/19 children with MOG antibodies continued
to have further demyelinating episodes. All episodes occurred
between 1 month and 3 years after the initial event. Three chil-
dren had up to two episodes of ON (Pat.16 (2 episodes of ON
2 and 3 years later); Pat.18 (1 episode of ON 2 months later);
Pat.19 (1 episode of ON 2 years later)) that were subsequently
classified as acute disseminating encephalomyelitis followed by
ON (ADEMON) as described previously.20 One child in this
subgroup had, in addition, two further episodes reminiscent of
ADEM (Pat.16). One child (Pat.17) experienced a second
episode of ADEM 3 month later that was classified as MDEM
(multiphasic acute disseminating encephalomyelitis; see online
supplementary eTable 1).
Follow-up antibody titres from up to six different time points
(19–61 months) were available from all four children. MOG
antibody titres remained high in all children apart from one
child with ADEMON (Pat.18), although it was lower as com-
pared to the initial titre. There was no difference in the magni-
tude of the initial MOG antibody level in children with only
one or more than one episode.
Neuroimaging
First, the presence of lesions in the initial brain and spinal MRI
was scored in five anatomical areas in addition to the configur-
ation of lesions.
All 19 children with ADEM and MOG antibodies had a
uniform MRI pattern, characterised by large, hazy and bilateral
lesions, and in the large majority of children, no atypical MRI fea-
tures, which was highly significant compared with children
without MOG antibodies (p=0.003; figure 2). In addition,
children with MOG antibodies had involvement of more anatom-
ical areas (p=0.035) and, in particular, the myelon (p=0.003). In
14/19 children with MOG antibodies, a spinal MRI was per-
formed, of whom 13 children had LETM (92.9%), which was also
highly significant in contrast to children without MOG antibodies,
who only showed an LETM in 4/12 spinal MRIs. Eight of 13 chil-
dren with LETM and MOG antibodies suffered from spinal symp-
toms, in contrast to children with absent MOG antibodies and
LETM (n=4), all of whom had spinal symptoms.
Eight of 14 children without MOG antibodies also had an
MRI with large, hazy and bilateral lesions (figure 3A). Six of 14
children with ADEM and absent MOG antibodies had, in add-
ition, two or more atypical MRI features. Well-defined lesions
were present in 5/6 children and combined with perpendicular
or periventricular lesion in 2 children (MS-like pattern; figure
3D–H). Diffuse white matter involvement was detected in 1/6
children (figure 3K) and predominantly small lesions in 2/6 chil-
dren (figure 3J). Further atypical features included cortical
lesions (n=1) (figure 3L), T1-hypointense lesions (n=1) or
lesions confined to only one anatomical region (n=3) (figure
3I). Only five patients showed contrast medium enhancement in
selected lesions in the inital MRI studies, revealing no differ-
ences between MOG positive or negative children.
Follow-up brain MRI was available from 17/19 children with
ADEM and MOG antibodies. Spinal cord imaging was per-
formed in 14/19 children. Ten children had a complete reso-
lution of white matter signal changes and four children
continued to show minor residual focal T2 lesions that were sig-
nificant compared with children without MOG antibodies
(p<0.001). Interestingly, 2/19 children with ADEM and MOG
antibodies had a follow-up study within the first month showing
already a dramatic improvement. Only 3/19 children with
ADEM typical MRI continued to have moderate or marked
residual findings such as persisting T2 lesions or atrophy.
In the group of 14 children without MOG antibodies, only 3
children—all without atypical MRI features—had a complete
resolution of signal changes. Eight of 14 children continued to
have moderate to marked residual MRI findings (figure 3F;
table 1). Four of these eight children with marked residual MRI
findings also had severe clinical residuals. Interestingly, one child
with ADEM and MOG antibodies, who subsequently developed
further ADEM episodes, also showed marked residual findings
on MRI such as generalised atrophy combined with a severe
therapy refractory seizure disorder.
Outcome
Clinical outcome was subdivided in normal (no neurological
symptoms), minor (mild neurological symptoms (eg, bladder
dysfunction) or moderate/severe (persistent significant neuro-
logical symptoms or sequelae such as epilepsy, learning difficul-
ties). Clinical recovery was significantly better in children
presenting with MOG-IgG antibodies than in seronegative chil-
dren (p=0.038) (table 1, see online supplementary eTable1).
Mild neurological sequelae were recorded only in 3/19 children
with MOG antibodies including mild bladder dysfunction and
mild spastic paraplegia. One child had a temporary seizure dis-
order, which is currently not treated. Only one child who had
further demyelinating antibodies developed a therapy-resistant
seizure disorder and was classified as a severe outcome.
Nine of 14 children with ADEM and absent MOG antibodies
had a normal outcome. However, 5/14 children continued to
have significant sequelae ranging from epilepsy, ataxia, marked
attention and learning difficulties to cognitive dysfunction (see
online supplementary eTable 1).
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Table 1 Comparison of demographic, clinical features, outcome and MRI of 33 paediatric patients with ADEM with or without MOG-IgG
antibodies
MOG-IgG at baseline
negative (n=14) positive (n=19) p Value
MOG-IgG titre (1:) at baseline 0 (0) 5120 (160–20 480)
MOG-IgG at follow-up 0/6 (0.0%) 8/18 (44.4%)
MOG-IgG titre (1:) at follow-up 0 (0) 80 (0–5120)
Decrease of MOG-IgG titre ≥2 steps 16/18 (88.9%)
CSF OCBs 1 (7.1%) 1/18 (5.6%) 1.000
CSF cell count/mL 10 (1–95) 53 (2–339) 0.038
Females 6 (40.0%) 9 (50.0%) 1.000
Age at onset (years) 7 (1–13) 4 (1–17) 0.084
Symptoms
Altered consciousness 13 (92.9%) 17 (89.5%) 1.000
Emotional/behaviour 6 (42.9%) 1 (5.3%) 0.026
Seizures 2 (14.3%) 2 (10.5%) 1.000
Optic neuritis 2 (14.3%) 3 (15.8%) 1.000
CN (III–XII) 6 (42.9%) 7 (36.8%) 1.000
Pyramidal signs 3 (21.4%) 3 (15.8%) 1.000
Ataxia 5 (35.7%) 10 (52.6%) 0.482
Sensory symptoms 2 (14.3%) 1 (5.3%) 0.561
Spinal symptoms 6 (42.9%) 10 (52.6%) 0.728
TM (symptom+MRI lesion) 4 (28.6%) 10 (52.6%) 0.286
Follow-up (months) 25 (6–61) 27 (5–92) 1.000
Multiphasic disease course 0 (0.0%) 4 (21.1%) 0.119
Clinical recovery
Complete 9 (64.3%) 15 (78.9%) 0.038
Minor residuals 0 (0.0%) 3 (15.8%)
Severe residuals 5 (35.7%) 1 (5.3%)
MRI areas affected
1. Supratentoriell WM 13 (92.9%) 16 (84.2%) 1.000
2. Thalamus/basal ganglia 9 (64.3%) 17 (89.5%) 0.238
3. Brainstem 8 (57.1%) 14 (73.7%) 0.459
4. Cerebellar 5 (35.7%) 12 (63.2%) 0.166
5. Spinal 4/12 (33.3%) 13/14 (92.9%) 0.003
Widespread score (items 1–5) 3 (1–5) 4 (2–5) 0.035
Brainstem/spinal lesions combined 8 (57.1%) 18 (94.7%) 0.026
LETM 4/12 (33.3%) 13/14 (92.9%) 0.003
Bilateral lesions 14 (100.0%) 19 (100.0%) 1.000
Large lesions >2 cm axial 13 (92.9%) 19 (100.0%) 0.424
Atypical MRI features
Only one MRI area affected 3 (21.4%) 0 (0%) 0.067
Diffuse WM involvement 1 (7.1%) 0 (0.0%) 0.424
Small lesions 2 (14.3%) 0 (0.0%) 0.090
T1-hypointense lesions 1 (7.1%) 0 (0.0%) 0.424
Well defined borders 5 (35.7%) 0 (0.0%) 0.008
Perpendicular 1 (7.1%) 0 (0.0%) 0.424
Periventricular 1 (7.1%) 1 (5.3%) 1.000
Cortical lesions 1 (7.1%) 1 (5.3%) 1.000
Number of atypical features 1 (1–3) 0 (0–1) 0.032
ADEM with ≤1 atypical MRI feature 8 (57.1%) 19 (100.0%) 0.003
MRI outcome available from 14/14 17/19
1. Complete resolution 3 (21.4%) 10 (58.8%) 0.036
2. Minor residuals 3 (21.4%) 4 (23.5%)
3. Moderate residuals 1 (7.1%) 2 (11.8%)
4. Marked residuals 7 (50.0%) 1 (5.9%)
ADEM, acute disseminating encephalomyelitis; CN, cranial nerves; CSF, cerebrospinal fluid; LETM, longitudinal extensive transverse myelitis; MOG, myelin oligodendrocyte glycoprotein;
OCBs, oligoclonal bands; TM, transverse myelitis; WM, white matter.
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Figure 2 Imaging of 6 paediatric patients with ADEM (acute disseminating encephalomyelitis) and MOG antibodies. (A–C) Cerebral and spinal
MRI of a 6-year-old patient (Pat.2) with MOG antibodies, who presented with headache, lethargy, lower limbs weakness, paraesthesia of the left
arm and leg combined with urinary and bowel incontinence, revealed large and blurred lesions (arrowheads) involving both hemispheres (A,
axial-T2) and the spinal cord with a longitudinal extensive lesion (LETM) (B, sagittal-T2). Two weeks later, the supratentorial and spinal lesions had
mostly resolved (C, axial-T2). (D–F) Cerebral MRI of a 4-year-old patient (Pat.13) with MOG antibodies, who presented with extreme lethargy,
paraparesis, a thalamic pain syndrome and headache, showed widespread and hazy lesions involving both hemispheres (D and E), the thalamus,
basal ganglia (E), brainstem, cerebellum (F, all axial-T2) and spinal cord with LETM (not shown). (G–I) Cerebral MRI of a 2-year-old patient (Pat.9)
with MOG antibodies, who presented with somnolence, opisthotonus, swallowing and respiratory problems, showed several large, blurredwhite
matter and cortical lesions (asterisks, atypical feature) (G,H, all axial-T2). 5 months later, the lesions had almost disappeared (I, axial T2). (J)
Cerebral MRI of a 5 year old patient (Pat.19) with MOG antibodies, who presented with headache, ataxia and lethargy, showed large and blurred
lesions involving the thalamus, basal ganglia ( J, axial-T2), brainstem, cerebellum and spinal cord with LETM (not shown). (K) Cerebral MRI of a
3-year-old patient (Pat.6) with MOG antibodies, who presented with fever, headache, dysarthria, gait disorder and right hemiparesis, showed large
and blurred lesions involving both hemispheres (K, axial-T2), the thalamus, basal ganglia, brainstem and spinal cord with LETM (not shown). (L)
Cerebral MRI of a 1-year-old patient (Pat.4) with MOG antibodies, who presented with ataxia, a tendency to fall, strabismus convergens and
lethargy, showed large and blurred lesions involving both hemispheres (L, axial-T2), the thalamus and cerebellum (not shown).
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Figure 3 Imaging of 7 paediatric patients with acute disseminating encephalomyelitis (ADEM) lacking MOG antibodies. (A–C) MRI of a 5-year-old
patient (Pat.21) with ADEM but without MOG antibodies revealed a MR-pattern reminiscent of children with ADEM and MOG antibodies with
widespread, blurred (arrowhead), large lesions involving both hemispheres (A, axial-T2), the thalamus and brainstem (not shown), and longitudinally
extensive transverse myelitis (LETM) (B, sagittal-T2). Three months later, the lesions had mostly resolved (C, axial-T2). (D–F) MRI of a patient
(Pat.31) lacking MOG antibodies who presented at the age of 11 years with aggressive behaviour, right haemiparesis and finally marked
somnolence showed mainly well-defined and periventricular (double arrowhead) MS (multiple sclerosis)-like lesions which classified as an atypical
feature (D). Cerebral MRI obtained one month later revealed extension of the previously noted lesions (E) which again decreased in size and signal
intensity three months later (F, all axial-T2). (G and H) Cerebral MRI of a 13-year-old patient (Pat.29) with ADEM and absent MOG antibodies, who
presented with symptoms including behavioural changes, bilateral motor weakness and ataxia, also showed large perpendicular lesions with mostly
well-defined borders (double arrowhead) and was classified as an MS like pattern (G, axial fluid attenuated inversion recovery; H, saggital-T2). The
patient had no further clinical episodes and also no new lesion formation. (I) Cerebral MRI of a 7-year-old patient (Pat.33) with ADEM lacking MOG
antibodies, who presented with symptoms including mental changes and a tetraparesis, was characterised by bilateral lesions mainly confined to the
basal ganglia with partly well-defined borders (I, axial-T2). (J) Cerebral MRI of a 4-year-old patient (Pat. 28) diagnosed with ADEM lacking MOG
antibodies, who presented with somnolence, aggression, urinary and bowel incontinence combined with ataxia and visual problems, revealed
predominantly small lesions in the white matter ( J, axial-T2), which did not change over time (not shown). (K) Cerebral MRI of a 1-year-old patient
(Pat.30) with ADEM and absent MOG antibodies, who presented with fever, somnolence and focal seizures, showed diffuse white matter
involvement without clear lesions (K, axial-T2). (L) Cerebral MRI of a 9-year-old patient (Pat.32) with ADEM lacking MOG antibodies, who presented
with severe headache, internuclear ophthalmoplegia, right haemiparesis, bladder dysfunction and stupor, showed mostly well-defined lesions
involving white matter, the basal ganglia, cortex (L, axial-T2), brainstem and cerebellum (not shown). MOG, myelin oligodendrocyte glycoprotein.
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DISCUSSION
We describe the clinical and neuroradiological features of paedi-
atric patients with ADEM with serum MOG antibodies, which
have been recently detected in a group of children and adults
with ADEM, ON and NMO spectrum disorders.7–15
In our cohort of 33 paediatric patients with ADEM, serum
MOG antibodies were detected in 19 children. From these 19
MOG IgG seropositive children, 15 had a monophasic disease
course and 4 continued to have further episodes. All children
with MOG antibody positive monophasic ADEM showed
declining antibody levels (available from 14 patients) over the
course of months to years, which is in line with previous
reports.7 All children with further demyelinating episodes (ON,
MDEM) had high MOG antibody levels, which still remain
high in 3/4 children even after a follow-up period of 61 months
as described previously.20
All children in our cohort had initially an encephalopathy
combined with focal neurological signs and an MRI compatible
with ADEM.
Comparison of the demographic data and initial clinical features
based on the MOG antibody status did not reveal any difference
apart from an elevated CSF cell count and, less often, behavioural/
emotional problems in children with MOG antibodies.
However, important differences were noted on MRI and clin-
ical outcome. Analysis of the initial MRI studies revealed a
nearly uniform pattern in all 19 children with ADEM and
MOG antibodies characterised by hazy, bilateral lesions without
clear boundaries, the absence of two or more atypical MRI fea-
tures and a more widespread distribution of lesions. In particu-
lar, the myelon was more often affected in children with MOG
antibodies with lesions spanning more than three segments
(LETM). Similar observations were recently made by others
who found that adults with an NMO spectrum disorder and
MOG antibodies also have frequently long lesions extending
even into the lumbar spinal cord.21 22
Another important finding was that in the majority of chil-
dren with MOG antibodies, signal changes were transient and
resolved in follow-up studies. On the other hand, in children
lacking MOG antibodies, only three children had a complete
resolution of signal changes and more than half of all children
without MOG antibodies continued to have moderate to
marked residual MRI findings. The transient nature of MRI
findings has been previously noted in individual patients with
autoimmune diseases and MOG antibodies.11 Interestingly,
Saadoun et al23 recently showed in a mouse model that intrapar-
enchymal injected MOG antibodies induced lesions, which were
transient and not associated with complement activation or
recruitment of inflammatory cells in the rodent brain.
The spectrum of MRI findings in children with ADEM and
absent MOG antibodies was less homogen and showed a wider
range of findings. One side of the spectrum included children
who had an MRI with large, bilateral and widespread lesions
but absent MOG antibodies. The other side of the spectrum
consisted of children who had absent MOG antibodies and an
MRI pattern with predominantly atypical features indicating
that a diagnosis other than ADEM should be entertained.
Initially, we had included 39 children who fulfilled the diagnos-
tic criteria of ADEM. However, in the follow-up period, six
children were assigned a different diagnosis. Interestingly, all six
children were negative for MOG antibodies and 5/6 children
had two or more atypical MRI features and no resolution of
lesions on follow-up. The fact that a substantial number of chil-
dren eventually will have another diagnosis has already been
pointed out by others, indicating the need for biomarkers that
help to predict the eventual course of the disease.3
Our findings have important clinical implications. Children
with ADEM who are seropositive for MOG antibodies and have
a typical MRI pattern form a distinct group of paediatric
patients associated with a good outcome. Further, we identified
a subgroup of MOG IgG negative children with an MRI
pattern, indistinguishable from MOG positive patients with
ADEM, indicating that other autoantibodies directed against
other antigens of the myelin sheath or glial components might
be involved in the disease process. Lastly, other diagnoses
should be sought in children with ADEM who have absent
MOG antibodies and atypical MRI features.
Several limitations should be addressed. Although the major-
ity of MRI studies were performed on a 1.5 T scanner, MRI was
performed in 10 children on scanners with a different field
strength, leading potentially to a different quality of images and
subsequent results. In addition, as detailed in previous studies,
children with ADEM and MOG antibodies can have subsequent
episodes of ON.20 24 Therefore, it would have been important
to assess if children with an initial episode of ADEM and MOG
antibodies also have involvement of the optic nerve.
Unfortunately, the MRI protocols did not explicitly include
sequences to evaluate the optic nerve.
CONCLUSIONS
Our study shows that patients with ADEM with MOG antibodies
had a uniformMRI characterised by large, bilateral and widespread
lesions with an increased frequency of LETM and a favourable clin-
ical outcome including the children with further demyelinating
events in contrast to children lacking MOG antibodies.
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